Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

Executive Summary

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

You may also be interested in...



Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed

The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker

EU: Pivotal Moment For Roche’s Faster-To-Apply Breast Cancer Combo

The European Medicines Agency is this week deciding whether or not to recommend pan-EU marketing approval for Roche’s subcutaneously injected fixed-dose combination of Perjeta and Herceptin. The agency is also deciding on a marketing application for the company's flu antiviral, baloxavir marboxil.

EU Review Gets Under Way For Lumasiran And Lonafarnib

The European Medicines Agency produces a monthly list of the marketing authorizations that are under review at the agency. The latest list contains just two new entries.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel